Related Experiment Video
Updated: Jul 11, 2026
07:58
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
[TREK-1: a potential target for novel antidepressants].
Yoshiaki Maruyama1, Mitsuhiko Yamada
1Department of Psychogeriatrics, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan. ymaru@ncnp.go.jp
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
|September 21, 2007
Summary
Deletion of the TREK-1 channel results in an antidepressant-like phenotype in mice, suggesting TREK-1 as a potential target for novel antidepressant drugs.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Serotonin (5-HT) is implicated in depression and antidepressant mechanisms.
- Molecular pathways of depression and its treatment remain unclear.
- TREK-1 channel deletion confers an antidepressant-like phenotype in mice.
Purpose of the Study:
- To review the molecular and functional properties of the TREK-1 channel.
- To explore TREK-1 as a potential target for novel antidepressants.
Main Methods:
- Review of existing literature on TREK-1 channels and their role in depression.
- Analysis of studies involving TREK-1 deficient mice and their behavioral and neurobiological responses.
- Examination of the interaction between selective serotonin reuptake inhibitors (SSRIs) and TREK-1 channels.
Main Results:
- TREK-1 deficient mice exhibit antidepressant-like behaviors.
- These mice show reduced corticosterone levels under stress.
- Enhanced serotonin neurotransmission and fluoxetine-induced hippocampal neurogenesis were observed in TREK-1 deficient mice.
- SSRIs inhibit both the serotonin transporter and the TREK-1 channel.
Conclusions:
- The TREK-1 channel plays a significant role in the pathophysiology and treatment of depression.
- TREK-1 is a promising molecular target for the development of new antidepressant therapies.
- Targeting TREK-1 may offer a novel therapeutic strategy for depression.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...